Shattuck Labs (STTK) Corporate presentation summary

Strategic focus and mission

• Dedicated to developing novel biologics for inflammatory and immune-mediated diseases, emphasizing scientific excellence and resource stewardship.

• Aims to create innovative therapeutics by challenging conventional approaches.

Pipeline and lead program

• Specializes in TNF receptor modulators and multifunctional fusion proteins, with a focus on the TL1A/DR3 pathway.

• Lead candidate SL-325 is a potential first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD), showing picomolar binding affinity and superior preclinical efficacy compared to TL1A blockers.

• Pipeline includes bispecific DR3 antibodies and bifunctional fusion proteins for autoimmune diseases and oncology.

Market opportunity

• IBD market projected to grow from $23.0B in 2023 to $33.3B by 2030, with high unmet need despite existing therapies.

• SL-325 targets a clinically validated axis in IBD, aiming for higher rates of endoscopic remission and durable disease control.